Promoted Content
Promoted Content

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Loading...

All Data

Filters Filter refresh
×
FILTER DATA :
News Type filter
    Company filter
      Product Type filter
        Deal Size filter
          Upfront Payment filter
            refresh

            Product Type Full Screen

            Companies Full Screen

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): DBPR115

            Therapeutic Area: Oncology Product Name: DBPR115

            Highest Development Status: Phase I Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable March 18, 2021

            Details:

            DBPR115 small molecule drug delivery system has a lower production cost and is less likely to cause adverse immune reactions.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): ACE1702

            Therapeutic Area: Oncology Product Name: ACE1702

            Highest Development Status: Phase I Product Type: Cell and Gene therapy

            Partner/Sponsor/Collaborator: Ridgeback Capital Investments

            Deal Size: $47.0 million Upfront Cash: Undisclosed

            Deal Type: Series B Financing March 16, 2021

            Details:

            The funding will be used to advance the company’s lead off-the-shelf natural killer (NK) cell therapy candidate, ACE1702, through clinical development in solid tumors, and to advance its preclinical NK and gamma delta T cell therapy pipeline into the clinic.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Pidnarulex

            Therapeutic Area: Oncology Product Name: CX-5461

            Highest Development Status: Phase I Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable December 24, 2020

            Details:

            In the CCTG Trial, CX-5461 demonstrated clinically significant and lasting benefits in patients with specific tumor biomarkers that were resistant to platinum and other chemotherapeutics.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): OBI-833

            Therapeutic Area: Oncology Product Name: OBI-833

            Highest Development Status: Phase I Product Type: Vaccine

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable November 19, 2020

            Details:

            In the trial, OBI-833 showed a favorable safety profile and generated detectable anti-Globo H IgM/IgG responses. The company’s novel first-in-class immuno-oncology portfolio against Globo H includes: Adagloxad Simolenin and OBI-833, a Globo H active immunotherapy vaccine.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): ACE1702,Cyclophosphamide,Fludarabine Phosphate

            Therapeutic Area: Oncology Product Name: ACE1702

            Highest Development Status: Phase I Product Type: Cell and Gene therapy

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable November 09, 2020

            Details:

            ACE1702 displayed higher cytotoxicity against multiple HER2-expressing cancer cell lines compared to the leading anti-HER2 antibody, trastuzumab, and its derived antibody-drug conjugate, trastuzumab emtansine (T-DM1).

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): ACE1702,Cyclophosphamide,Fludarabine Phosphate

            Therapeutic Area: Oncology Product Name: ACE1702

            Highest Development Status: Phase I Product Type: Cell and Gene therapy

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable November 02, 2020

            Details:

            Poster titled A potent and off-the-shelf oNK cell therapy product targets HER2+ cancer cells and resists suppressive tumor microenvironment will be presented at the at The Society for Immunotherapy of Cancer 35th Anniversary Annual Meeting.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): ACE1702,Cyclophosphamide,Fludarabine Phosphate

            Therapeutic Area: Oncology Product Name: ACE1702

            Highest Development Status: Phase I Product Type: Cell and Gene therapy

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable August 18, 2020

            Details:

            The study will evaluate the safety and tolerability, pharmacodynamics, and preliminary efficacy of ACE1702 in patients with advanced or metastatic HER2-expressing solid tumors not amenable to surgery or other therapeutic options.